Key Points
- CAO Brett Hagen sold 1,915 shares on March 20 at an average price of $6.72 for proceeds of $12,868.80, according to an SEC filing.
- Kalaris reported ($0.44) EPS for the quarter—beating estimates by $0.12—and the stock carries a market cap of $149.05M with a consensus analyst rating of "Moderate Buy" and a $14 price target.
- Institutional investors own 66.05% of the company; State Street increased its stake by 12.4% in Q4 and several other institutions initiated or added small positions.
Kalaris Therapeutics Inc. (NASDAQ:KLRS - Get Free Report) CAO Brett Hagen sold 1,915 shares of the firm's stock in a transaction on Friday, March 20th. The shares were sold at an average price of $6.72, for a total transaction of $12,868.80. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.
Kalaris Therapeutics Stock Performance
Shares of Kalaris Therapeutics stock opened at $6.50 on Tuesday. The company has a market capitalization of $149.05 million, a P/E ratio of -1.54 and a beta of -0.13. The company has a fifty day moving average of $9.30 and a 200 day moving average of $7.35. Kalaris Therapeutics Inc. has a fifty-two week low of $2.14 and a fifty-two week high of $12.26.
Kalaris Therapeutics (NASDAQ:KLRS - Get Free Report) last posted its quarterly earnings results on Tuesday, March 17th. The company reported ($0.44) EPS for the quarter, beating analysts' consensus estimates of ($0.56) by $0.12.
Wall Street Analysts Forecast Growth
Several research firms have weighed in on KLRS. Wall Street Zen upgraded Kalaris Therapeutics from a "sell" rating to a "hold" rating in a research note on Sunday, March 15th. Weiss Ratings reissued a "sell (d-)" rating on shares of Kalaris Therapeutics in a report on Monday, December 29th. Citigroup restated an "outperform" rating on shares of Kalaris Therapeutics in a research report on Thursday, December 18th. Finally, Chardan Capital initiated coverage on shares of Kalaris Therapeutics in a research note on Tuesday, December 23rd. They set a "buy" rating and a $19.00 target price for the company. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $14.00.
View Our Latest Research Report on Kalaris Therapeutics
Institutional Investors Weigh In On Kalaris Therapeutics
Institutional investors have recently modified their holdings of the stock. State Street Corp boosted its holdings in shares of Kalaris Therapeutics by 12.4% in the 4th quarter. State Street Corp now owns 25,410 shares of the company's stock worth $214,000 after purchasing an additional 2,800 shares during the period. Nano Cap New Millennium Growth Fund L P purchased a new position in Kalaris Therapeutics during the fourth quarter worth $34,000. Barclays PLC bought a new position in Kalaris Therapeutics during the fourth quarter valued at $51,000. Johnson Financial Group Inc. bought a new position in Kalaris Therapeutics during the third quarter valued at $58,000. Finally, Keel Point LLC purchased a new stake in shares of Kalaris Therapeutics in the fourth quarter valued at $86,000. 66.05% of the stock is owned by institutional investors.
Kalaris Therapeutics Company Profile
(
Get Free Report)
Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
